Abstract
Objective: To determine whether first-trimester measurements of maternal serum PAPP-A and free βhCG levels were associated with adverse pregnancy outcomes.
Study Design: First trimester maternal serum free βhCG and PAPP-A were measured in 490 singleton pregnancies. Pregnancies were followed by the fetal-maternal unit, and predictive efficacy of these markers for small for gestational age (SGA) babies, gestational diabetes mellitus and hypertensive disorders were analyzed by cut-off values determined by using a ROC analysis, and also, by using the fifth percentile as the cut-off value.
Results: The sensitivities for PAPP-A in predicting pregnancies with a SGA baby and those complicated by a hypertensive disorder were 49% and 73%, respectively, when optimal cut-off values were used. Specificities were 76% and 65%, respectively. Serum free βhCG had no predictive value for individual pregnancy outcomes.
Conclusion: Efficacy of first trimester maternal serum markers in predicting adverse pregnancy outcome is low. Even after optimization of cut-off values, these markers do not appear to be clinically acceptable as an effective tool for screening for adverse pregnancy outcomes.
References
1 Bindra R, V Heath, A Liao, K Spencer, KH Nicolaides: One-stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol20 (2002)10.1046/j.1469-0705.2002.00808.xSearch in Google Scholar
2 Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes28 (1979)10.2337/diab.28.12.1039Search in Google Scholar
3 De Leon J, G Sifuentes, C Hopkins, V Noble, T Gimpel, T Myles, J Santolaya-Forgas: Maternal serum free beta-hCG levels in uncomplicated pregnancies at the 10th–15th week of gestation and the development of obstetric complications. J Reprod Med49 (2004)Search in Google Scholar
4 Dugoff L, JC Hobbins, FD Malone, TF Porter, D Luthy, CH Comstock, G Hankins, RL Berkowitz, I Merkatz, SD Craigo, IE Timor-Tritsch, SR Carr, HM Wolfe, J Vidaver, ME D'Alton: First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol191 (2004)10.1016/j.ajog.2004.06.052Search in Google Scholar
5 Hsieh TT, TH Hung, JJ Hsu, WY Shau, CW Su, FJ Hsieh: Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population. Obstet Gynecol89 (1997)10.1016/S0029-7844(97)00151-8Search in Google Scholar
6 Krantz D, L Goetzl, JL Simpson, E Thom, J Zachary, TW Hallahan, R Silver, E Pergament, LD Platt, K Filkins, A Johnson, M Mahoney, WA Hogge, RD Wilson, P Mohide, D Hershey, R Wapner: Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol191 (2004)10.1016/j.ajog.2004.05.068Search in Google Scholar
7 Krantz DA, TW Hallahan, F Orlandi, P Buchanan, JW Larsen, Jr, JN Macri: First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol96 (2000)10.1097/00006250-200008000-00010Search in Google Scholar
8 Morssink LP, LH Kornman, TW Hallahan, MD Kloosterman, JR Beekhuis, BT de Wolf, A Mantingh: Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn18 (1998)10.1002/(SICI)1097-0223(199802)18:2<147::AID-PD231>3.0.CO;2-WSearch in Google Scholar
9 Ong CY, AW Liao, K Spencer, S Munim, KH Nicolaides: First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. Bjog107 (2000)10.1111/j.1471-0528.2000.tb11618.xSearch in Google Scholar
10 Pedersen JF, S Sorensen, S Ruge: Human placental lactogen and pregnancy-associated plasma protein A in first trimester and subsequent fetal growth. Acta Obstet Gynecol Scand74 (1995)10.3109/00016349509024379Search in Google Scholar
11 Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol183 (2000)10.1016/S0002-9378(00)40820-3Search in Google Scholar
12 Smith GC, EJ Stenhouse, JA Crossley, DA Aitken, AD Cameron, JM Connor: Early-pregnancy origins of low birth weight. Nature417 (2002)10.1038/417916aSearch in Google Scholar
13 Smith GC, EJ Stenhouse, JA Crossley, DA Aitken, AD Cameron, JM Connor: Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab87 (2002)10.1210/jcem.87.4.8430Search in Google Scholar
14 Snijders RJ, P Noble, N Sebire, A Souka, KH Nicolaides: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet352 (1998)10.1016/S0140-6736(97)11280-6Search in Google Scholar
15 Tul N, S Pusenjak, J Osredkar, K Spencer, Z Novak-Antolic: Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn23 (2003)10.1002/pd.735Search in Google Scholar
16 Wapner R, E Thom, JL Simpson, E Pergament, R Silver, K Filkins, L Platt, M Mahoney, A Johnson, WA Hogge, RD Wilson, P Mohide, D Hershey, D Krantz, J Zachary, R Snijders, N Greene, R Sabbagha, S MacGregor, L Hill, A Gagnon, T Hallahan, L Jackson: First-trimester screening for trisomies 21 and 18. N Engl J Med349 (2003)10.1056/NEJMoa025273Search in Google Scholar
17 Yaron Y, M Cherry, RL Kramer, JE O'Brien, M Hallak, MP Johnson, MI Evans: Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol181 (1999)10.1016/S0002-9378(99)70334-0Search in Google Scholar
18 Yaron Y, S Heifetz, Y Ochshorn, O Lehavi, A Orr-Urtreger: Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn22 (2002)10.1002/pd.407Search in Google Scholar PubMed
19 Yaron Y, Y Ochshorn, S Heifetz, O Lehavi, Y Sapir, A Orr-Urtreger: First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome. Fetal Diagn Ther17 (2002)10.1159/000065384Search in Google Scholar PubMed
©2005 by Walter de Gruyter Berlin New York
